Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
|Articles|December 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
ASA404 lung ca trial expanded
ASA404 lung cancer trial expanded
Advertisement
LONDON—Antisoma plc announced that its licensing partner Novartis plans to start a pivotal phase III trial of ASA404 in non-small-cell lung cancer in early 2008. This trial has been expanded to include patients with nonsquamous as well as squamous disease, a change that more than doubles the population of NSCLC patients addressed by the trial.
Articles in this issue
almost 19 years ago
Third-line single-agent cetuximab ups overall survivalalmost 19 years ago
Modern multislice CT propels pancreas imaging forwardalmost 19 years ago
Sorafenib gets ok for liver canceralmost 19 years ago
Celgene to acquire Pharmionalmost 19 years ago
Novacea halts ASCENT-2 trialalmost 19 years ago
RT/temozolomide raises possibility of cure in glioblastomaalmost 19 years ago
Brachytherapy as effective in younger as in older menalmost 19 years ago
MMA not harming patientsalmost 19 years ago
Kinase inhibitor may prevent RT-induced lung injuryalmost 19 years ago
FDA approves lower starting dose for dasatinib for CMLAdvertisement
Related to this article
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS
5